Semaglutide and blood pressure: an individual patient data meta-analysis
-
Kennedy C, Hayes P, Cicero AFG, Dobner S, Le Roux CW, McEvoy JW, Zgaga L, Hennessy M.
Semaglutide and blood pressure: an individual patient data meta-analysis Eur Heart J
Publication Category: Medications
Laxative Properties of Microencapsulated Oleic Acid Delivered to the Distal Small Intestine in Patients with Constipation after Bariatric Surgery or Treatment with Glucagon-Like- Peptide 1 Analogues
-
Al-Humadi AW, Al-Najim W, Bleiel S, le Roux CW.
Laxative Properties of Microencapsulated Oleic Acid Delivered to the Distal Small Intestine in Patients with Constipation after Bariatric Surgery or Treatment with Glucagon-Like- Peptide 1 Analogues Obes Surg
Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings
-
Kelly AS, Bahlke M, Baker JL, de Beaufort C, Belin RM, Fonseca H, Hale PM, Holm JC, Hsia DS, Jastreboff AM, Juliusson PB, Murphy M, Pak J, Paul E, Rudolph B, Srivastava G, Tornøe CW, Weghuber D, Fox CK.
Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings Pediatr Obes
Metabolomic Effects of Liraglutide Therapy on the Plasma Metabolomic Profile of Patients with Obesity
-
Alfadda AA, Abdel Rahman AM, Benabdelkamel H, AlMalki R, Alsuwayni B, Alhossan A, Aldhwayan MM, Abdeen GN, Miras AD, Masood A.
Metabolomic Effects of Liraglutide Therapy on the Plasma Metabolomic Profile of Patients with Obesity Metabolites
PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes
- Saravanan P, Bell H, Braae UC, Collins E, Deinega A, Dhatariya K, Machell A, Trent A, Strzelecka A. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes Adv Ther
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
-
Stefanou MI, Palaiodimou L, Theodorou A, Safouris A, Fischer U, Kelly PJ, Dawson J, Katan M, Katsanos AH, Lambadiari V, Giannopoulos S, Alexandrov AV, Siasos G, Tsivgoulis G.
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis Ther Adv Neurol Disord
GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea
-
O'Donnell C, Ryan O, Hogan AE, Killick D, Crilly S, Dodd JD, Murphy DJ, Ryan S, O'Shea D.
GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea Obesity (Silver Spring)
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting
-
Alabduljabbar K, Alsaqaaby M, Neff KJ, Crotty M, le Roux CW.
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting Endocrine
New therapies for obesity
-
Papamargaritis D, le Roux CW, Holst JJ, Davies MJ.
New therapies for obesity Cardiovasc Res